Christopher Bishop Selected Research

5-HT1A Serotonin Receptor

11/2013	Effects of 5-HT1A receptor stimulation on striatal and cortical M1 pERK induction by L-DOPA and a D1 receptor agonist in a rat model of Parkinson's disease.
6/2013	The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.
5/2013	Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.
9/2011	Role of the primary motor cortex in L-Dopa-induced dyskinesia and its modulation by 5-HT1A receptor stimulation.
6/2011	Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats.
12/2008	Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat.
7/2008	Effects of coincident 5-HT1A receptor stimulation and NMDA receptor antagonism on L-DOPA-induced dyskinesia and rotational behaviors in the hemi-parkinsonian rat.
7/2007	The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
5/2006	MDMA and fenfluramine reduce L-DOPA-induced dyskinesia via indirect 5-HT1A receptor stimulation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Christopher Bishop Research Topics

Disease

46	Dyskinesias (Dyskinesia) 07/2022 - 11/2003
41	Parkinson Disease (Parkinson's Disease) 07/2022 - 05/2006
2	Movement Disorders (Movement Disorder) 01/2022 - 12/2013
2	Neuroinflammatory Diseases 12/2019 - 01/2019
2	Shock 11/2019 - 07/2013
1	Neurodegenerative Diseases (Neurodegenerative Disease) 07/2022
1	Diphtheria 01/2021
1	Disease Progression 01/2021
1	Gliosis 01/2021
1	Neoplasms (Cancer) 11/2020
1	Prostatic Neoplasms (Prostate Cancer) 11/2020
1	Sleep Wake Disorders 01/2019
1	Inflammation (Inflammations) 04/2016
1	Asthma (Bronchial Asthma) 11/2015
1	Seasonal Allergic Rhinitis (Hay Fever) 11/2015
1	Eczema 11/2015
1	Hypokinesia (Bradykinesia) 08/2014
1	Tremor (Tremors) 08/2014
1	Respiratory Sounds (Crackle) 05/2014

Drug/Important Bio-Agent (IBA)

45	Levodopa (L Dopa)FDA LinkGeneric 07/2022 - 08/2005
29	Dopamine (Intropin)FDA LinkGeneric 07/2022 - 08/2005
10	Serotonin (5 Hydroxytryptamine)IBA 07/2022 - 03/2003
9	5-HT1A Serotonin ReceptorIBA 11/2013 - 05/2006
7	Oxidopamine (6 Hydroxydopamine)IBA 01/2021 - 05/2006
5	SK&F 81297IBA 01/2019 - 12/2008
3	Vilazodone HydrochlorideIBA 07/2022 - 11/2018
3	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2021 - 01/2018
3	Cholinergic Agents (Cholinergics)IBA 01/2021 - 01/2018
3	salicylhydroxamic acid (SHAM)IBA 01/2021 - 06/2011
3	Dopamine Receptors (Dopamine Receptor)IBA 01/2020 - 07/2007
3	Glutamic Acid (Glutamate)FDA Link 11/2017 - 06/2011
2	Dopamine D3 ReceptorsIBA 03/2021 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 01/2021 - 11/2016
2	Phosphotransferases (Kinase)IBA 01/2021 - 11/2013
2	gamma-Aminobutyric Acid (GABA)IBA 01/2020 - 01/2016
2	2,3,4,5- Tetrahydro- 7,8- dihydroxy- 1- phenyl- 1H- 3- benzazepine (SKF 38393)IBA 01/2020 - 01/2017
2	QuinpiroleIBA 01/2019 - 07/2015
2	Norepinephrine (Noradrenaline)FDA LinkGeneric 01/2018 - 07/2013
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2018 - 01/2016
2	Pharmaceutical PreparationsIBA 09/2017 - 04/2016
2	Immunoglobulin E (IgE)IBA 11/2015 - 05/2014
2	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 09/2009 - 05/2006
2	hydroxide ionIBA 05/2009 - 12/2008
1	1- (1- benzyl- 4- hydroxypiperidin- 4- ylmethyl)- 2(1H)- pyridinoneIBA 07/2022
1	VortioxetineIBA 07/2022
1	Amantadine (Aman)FDA LinkGeneric 01/2022
1	Excitatory Amino Acid AntagonistsIBA 01/2022
1	EnzymesIBA 01/2021
1	Protein Kinases (Protein Kinase)IBA 01/2021
1	Biological ProductsIBA 01/2021
1	urotensin IIIBA 01/2021
1	3,4,4a,10b- tetrahydro- 4- propyl- 2H,5H- (1)benzopyrano(4,3- b)- 1,4- oxazin- 9- olIBA 01/2020
1	Tropicamide FDA LinkGeneric 01/2019
1	AutoreceptorsIBA 01/2019
1	Trihexyphenidyl (Artane)FDA LinkGeneric 01/2019
1	Serotonin ReceptorsIBA 11/2018
1	Tyrosine 3-Monooxygenase (Tyrosine Hydroxylase)IBA 11/2017
1	Glutamate Receptors (Glutamate Receptor)IBA 11/2017
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 11/2017
1	AntioxidantsIBA 09/2017
1	NeurotoxinsIBA 09/2017
1	ropinirole (Requip)FDA LinkGeneric 09/2017
1	3- chloro- 4- fluorophenyl- (4- fluoro- 4- (((5- methyl- 6- methylaminopyridin- 2- ylmethyl)amino)methyl)piperidin- 1- yl)methanoneIBA 01/2017
1	3- chloro- 4- fluorophenyl- (4- fluoro- 4- (((5- methylpyrimidin- 2- ylmethyl)amino)methyl)piperidin- 1- yl)methanoneIBA 01/2017
1	vanoxerine (I 893)IBA 11/2016
1	Citalopram FDA LinkGeneric 11/2016
1	nisoxetineIBA 11/2016
1	Naproxen (Naprosyn)FDA LinkGeneric 04/2016
1	Clomipramine (Anafranil)FDA LinkGeneric 03/2016
1	Tricyclic Antidepressive Agents (Tricyclic Antidepressants)IBA 03/2016
1	alpha- Amino- 3- hydroxy- 5- methyl- 4- isoxazolepropionic Acid (AMPA)IBA 01/2016
1	AllergensIBA 11/2015
1	Therapeutic UsesIBA 08/2015
1	atipamezoleIBA 08/2015
1	Clonidine (ST 155)FDA LinkGeneric 08/2015
1	beta Adrenergic ReceptorsIBA 07/2015
1	Propranolol (Inderal)FDA LinkGeneric 07/2015
1	Biomarkers (Surrogate Marker)IBA 11/2013
1	Interleukin-1 (Interleukin 1)IBA 07/2013
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 07/2013
1	Dihydrotachysterol (AT 10)IBA 06/2013
1	Dopamine Agonists (Dopamine Agonist)IBA 06/2013
1	alpha- (4- fluorophenyl)- 4- (5- fluoro- 2- pyrimidinyl)- 1- piperazine butanolIBA 06/2013
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 05/2013
1	Tuberculin (PPD)IBA 05/2013
1	Messenger RNA (mRNA)IBA 05/2013
1	pre-prodynorphinIBA 05/2013
1	Apomorphine FDA Link 09/2012
1	Selective Serotonin Reuptake Inhibitors (Serotonin Reuptake Inhibitors)IBA 09/2012
1	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 09/2012
1	Adrenergic Antagonists (Antiadrenergic Agents)IBA 01/2012
1	Adrenergic Receptors (Adrenergic Receptor)IBA 06/2011

Therapy/Procedure

18	Therapeutics 07/2022 - 11/2003
3	Drug Therapy (Chemotherapy) 08/2014 - 05/2006
1	Image-Guided Radiotherapy 11/2020
1	Radiotherapy 11/2020
1	Foot Orthoses 11/2019
1	Transcranial Magnetic Stimulation 01/2016
1	Injections 11/2013
1	Denervation 01/2012